[用于急性淋巴细胞白血病的CD19向T细胞的化学抗原受体 (CAR) ]
Yoshiyuki Takahashi1, Nobuhiro Nishio2
1Department of Pediatrics, Nagoya University Graduate School of Medicine.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|October 29, 2023
概括
化学抗原受体 (CAR-T) 治疗对急性淋巴细胞白血病有前途,但复发率为50%. 研究正在探索复发和成本有效的CAR-T替代品的预测因素.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞疗法 细胞疗法
关键词:
急性淋巴细胞白血病 (Acute Lymphoblastic Leukemia) 是一种急性淋巴细胞白血病.在CART-T中,我们可以使用CAR-T.CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19 CD19在PiggyBac的转位子上更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.4K
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.3K